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Abstract
Background: This study analyzed visits for and factors associated with gout and gout medication treatment trends
for the years 2007–2011 in the United States given the introduction of febuxostat, the first new treatment option
for gout in over 40 years, which was introduced to the market in 2009.
Methods: This study was a retrospective, cross-sectional, observational study of patients age 20 and older seen by
providers who participated in the National Ambulatory Medical Care Survey (NAMCS), the National Hospital
Ambulatory Medical Care Survey Outpatient Department (NHAMCS-OPD) or Emergency Department (NHAMCS-ED)
in the United States. The outcome of interest was visits for gout diagnosis and visits where a gout medication was
prescribed.
Results: Approximately 1.2% of visits had a diagnosis of gout. There was a significant increase in the percentage of
visits with a diagnosis of gout in years 2009–2011 compared to 2007–2008, which remained after adjusting for
covariates of interest. Groups more likely to have a visit with gout included those ≥65 and 45–64 (both as
compared to those 20–44), the African-American and ‘Other’ race groups (as compared to Caucasians) and those
on a diuretic. Groups less likely to have a visit with gout included females, Hispanic/Latinos, those with insurance
type of ‘Other’ and Medicaid (both as compared to private insurance) and visits to a hospital emergency setting (as
compared to physician’s office visits).
Conclusion: Although there was a significant increase in visits where gout is diagnosed across study years, the
overall percentage of visits with a gout diagnosis is low in the US population. Treatment trends over the study
years has remained consistent, with the introduction of febuxostat appearing to have little impact for the study
years through 2011.
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Background
Gout is a type of inflammatory arthritis associated with
the formation of urate crystals in the joints. It is esti-
mated that approximately 4% of Americans are affected,
but previous research has shown the prevalence of gout
is increasing [1]. Contributing factors to gout include in-
crease in obesity, hypertension, and purine-rich diets [2].
The severity and progression of gout has been directly
correlated to an increase in age. [3] Gout is known to be
more predominant in males, but is seen in postmeno-
pausal women. The prevalence of gout is higher in Afri-
can Americans as compared to Caucasians, with
increasing prevalence overall across all demographics
[3]. Prior to 2009, pharmacological treatment options for
gout had not changed in many years. A new treatment
option, febuxostat, was approved by the Food and Drug
Administration in February 2009 [4].
No studies have evaluated the proportion of visits with
a gout diagnosis since 2009 when febuxostat was intro-
duced to the market. Previous studies have shown that
an above normal BMI, hypertension, dyslipidemia, use of
a diuretic and older age are associated with an increased
risk of gout [5–10].
With the first new gout therapy in over 40 years intro-
duced to the market in 2009, this study sought to evalu-
ate changes in gout-related ambulatory and emergency
department visits for the years 2007 through 2011 (the
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most recent data available) as well as assess factors asso-
ciated with gout [11]. Additionally, gout treatment
trends were plotted to determine the impact of febuxo-
stat on gout therapy since its introduction to the market.
Methods
This retrospective, cross-sectional, observational study
analyzed data collected in the National Ambulatory
Medical Care Survey (NAMCS) and the National
Hospital Ambulatory Medical Care Survey Outpatient
Department & Emergency Department (NHAMCS-
OPD/NHAMCS-ED) during the years 2007–2011. Hun-
dreds of reports, manuscripts and books based on data
from these widely utilized and respected surveys have
been published since the 1970s (https://www.cdc.gov/
nchs/data/ahcd/namcs_nhamcs_publication_list.pdf ).
The NHAMCS is an annual, national probability sam-
ple of ambulatory visits made to non-federal, general,
and short-stay hospitals in the US conducted by the
Centers for Disease Control and Prevention, National
Center for Health Statistics (NCHS). The multi-staged
sampling design is composed of four stages and includes
visits to both selected emergency care departments as
well as hospital outpatient departments [12–14]. The
NAMCS is an annual, national probability sample of
visits made to the offices of non-federally employed phy-
sicians classified by the American Medical Association
or the American Osteopathic Association as “office-
based, patient care” (excluding anesthesiologists, pathol-
ogists and radiologists) [12–14]. For more information
regarding the survey instruments, scope and sample de-
sign, data collection and processing, estimation proce-
dures and reliability of survey estimates, go to http://
www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm.
NAMCS, NHAMCS-OPD and NHAMCS-ED datasets
covering five years (2007–2011) were included in this
study. Patients 20 or older from any of the three data-
bases were coded as included in the final analysis data-
set. There were no exclusions for the study. Across all
five years a total of 128,734 raw records in the
NHAMCS-OPD, 126,836 raw records in the NHAMCS-
ED and 126,651 in the NAMCS databases met the inclu-
sion criteria (382,221 combined). The study was submit-
ted to the Campbell University Institutional Review
Board and received an exemption due to the data
sources used being publicly available and de-identified.
As such, since this research was based solely on the ana-
lysis of previously collected, de-identified data, it com-
plies with the Helsinki Declaration.
The survey data were analyzed using the sampled visit
weight that is the product of the corresponding sampling
fractions at each stage in the sample design. The sam-
pling weights have been adjusted by NCHS for survey
nonresponse as appropriate within each database,
yielding unbiased national annual estimates of visit oc-
currences, percentages, and characteristics [12].
Because of the complex sample design, sampling er-
rors were determined using the SAS SURVEYFREQ and
SURVEYLOGISTIC procedures which take into account
the clustered nature of the sample [15]. The appropriate
NOMCAR and DOMAIN statements/options were im-
plemented in these procedures as recommended by the
NCHS [12].
The dependent variable of interest was a diagnosis of
gout, where the denominator is the number of visits
meeting the inclusion/exclusion criteria. A diagnosis of
gout was defined by the appropriate diagnosis codes
found in any of the DIAG1-DIAG3 diagnosis fields or
appropriate gout medication codes for allopurinol,
febuxostat, colchicine, probenecid, and colchicine-
probenecid found in any of the DRUGID1-DRUGID8
medication fields.
Rao-Scott chi-square tests were used to analyze
whether the proportion of visits with a diagnosis of gout
differs by year group (2007–2008 vs. 2009–2011) and
whether any association exists between visits with a
diagnosis of gout and each of the following variables:
age, sex, race, ethnicity, region (US geographic regions
included Northeast, Midwest, South, and West), metro-
politan statistical area (MSA), insurance status (private,
Medicaid or Children’s Health Insurance Program
[CHIP]/State Children’s Health Insurance Program
[SCHIP], Medicare, and other [worker’s compensation,
self-pay, no charge/charity, other], setting type (phys-
ician office, hospital outpatient department, hospital
emergency department) and diuretic use. These variables
were grouped for analysis as shown in Table 1. Odds ra-
tios (ORs), corresponding 95% confidence intervals (CIs)
and p-values were reported.
A multivariable logistic regression model was also
constructed in order to evaluate the predictive value
of all the independent variables of interest simultan-
eously on visits with a diagnosis of gout, adjusting for
covariates of interest. As a primary model filter, only
variables with an overall chi-square test of association
p-value < 0.2 were included in the multivariable
model (year group was included regardless). ORs with
corresponding 95% CIs and p-values for each level of
each variable included in the model (in comparison
to each variable’s reference group) were reported. No
collinearity issues between the independent variables
included in the model were found. All analyses were
generated using SAS software, version 9.3. Plots of
the percentage of visits per year with gout medication
by drug class and individual drug were constructed to
descriptively assess gout treatment trends.
Per NCHS recommendations, any variable with a sur-
vey estimate based on either less than 30 records, a
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relative standard error of more than 30%, or more than
30% missing data was excluded from the analyses due to
potential unreliability [12]. As a result, the variables of
interest weight status, tobacco use, depression, hyperten-
sion, and diabetes were excluded from all analyses due
to not meeting one or more of the above listed criteria.
Missing values were treated as missing in the statistical
evaluation. No adjustments for multiple comparisons
were made and p-values < 0.05 were considered statisti-
cally significant.
Results
During the study period (2007–2011), the NAMCS,
NHAMCS-OPD, and NHAMCS-ED datasets include a
total of 495,370 patient visits (unweighted, raw data). A
total of 382,221 patient visits within this five-year period
met the inclusion criteria and were included in this
study (Table 1). Most variables had no missing data,
however, ethnicity, race and insurance status were miss-
ing 21, 16 and 5%, respectively. Gout was diagnosed in
just over 1.2% of all patient visits. More patient visits oc-
curred during the more recent half of the study period
(61% in the years 2009–2010). The mean age (SE) was
53.9 (0.23) years, with a similar percentage of patients in
each of the three age groups. Of the patient visits
included in the analyses, 61% were female, 82% were
Caucasian, 14% were African-American, and 11% were
Hispanic/Latino. Nearly twice as many visits occurred in
the South (38%) as compared to the other regions (21%
in the Midwest, 21% in the West and 20% in the North-
east). However, visits in metropolitan areas represented
87% of the study total. Private insurance was presented
at the majority of all patient visits (50%), with Medicare
presented at 30% of visits and Medicaid at 10%. The vast
majority of visits occurred in a physician’s office (82%),
reflecting the NAMCS survey data (collected in phys-
ician offices). Only 7% of patient visits reported diuretic
use.
The primary analysis showed a 30% relative increase in
the percentage of patients who had a visit with a diagno-
sis of gout in the years 2009–2011 compared to 2007–
2008 (1.3% vs. 1.0%, respectively; OR 1.28, 95% CI 1.10–
1.49) (Table 2). The individual chi-square tests of the
other covariates of interest that comprised the first part
of the secondary analysis, showed a significant associ-
ation between visits with a diagnosis of gout and the fol-
lowing variables: age, sex, ethnicity, race group,
insurance status, setting type, region and diuretic use.
See the univariable columns in Table 2 for the details of
these individual associations with visits for a diagnosis of
gout.
The weighted multivariable logistic regression model,
allowing adjustment for the effect of potentially
Table 1 Demographics and Patient Characteristics (N = 382,221)a
Characteristic No. (%) of Patient Visitsb
Observation Period
2009–2011 588,791,594 (61)
2007–2008 375,839,802 (39)
Age (years)
Mean (SE) 53.9 (0.23)
Age Group
≥65 299,032,423 (31)
45–64 351,209,142 (36)
20–44 314,389,831 (33)
Sex
Female 587,394,025 (61)
Male 377,237,371 (39)
Race
Other 33,516,436 (5)
African-American 99,604,070 (14)
Caucasian 602,374,076 (82)
Ethnicity
Hispanic/Latino 79,262,491 (11)
Non-Hispanic/Latino 630,345,157 (89)
Region
Northeast 189,690,837 (20)
Midwest 206,775,296 (21)
West 201,670,759 (21)
South 366,494,504 (38)
MSA
Non-MSA 120,846,147 (13)
MSA 843,785,249 (87)
Insurance Status
Other 98,736,670 (11)
Medicaid 88,374,398 (10)
Medicare 280,902,288 (30)
Private Insurance 461,730,141 (49)
Setting Type
Hospital Emergency 94,712,528 (10)
Hospital Outpatient 78,137,131 (8)
Physician’s Office 791,781,738 (82)
Diuretic Use
Yes 71,243,249 (7)
No 893,388,147 (93)
Gout
Yes 11,769,697 (1)
No 952,861,700 (99)
MSA Metropolitan Statistical Area
aUnweighted, raw study sample size
bSurvey weighting and clusters accounted for reflecting unbiased,
national annual estimates of visit occurrences for the portion of the
population meeting the study inclusion/exclusion criteria
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important variables, demonstrated that significant asso-
ciations remained between visits with a gout diagnosis
and age group (≥65 and 45–64 vs. 20–44), sex, ethnicity,
race group (‘Other’ vs. Caucasian as well as now
African-American vs. Caucasian), insurance status
(Other and Medicaid vs. private insurance, but no longer
Table 2 Gout Predictor Variables, Univariable and Multivariable Analyses* Data are given as number (%) of patients
Univariable Multivariable
Parameter Gout (%) No Gout (%) OR (95% CI) P OR (95% CI) P
Observation Period
2009–2011 7,849,421 (1.3) 580,942,174 (98.7) 1.28 (1.10–1.49) 0.0010 1.24 (1.02–1.52) 0.0346
2007–2008 3,920,276 (1.0) 371,919,526 (99.0) Referent – Referent –
Age Group (years)
≥ 65 7,113,034 (2.4) 291,919,369 (97.6) 8.64 (7.04–10.60) < 0.0001 4.94 (3.69–6.62) < 0.0001
45–64 3,772,290 (1.1) 347,436,851 (98.9) 3.85 (3.11–4.77) < 0.0001 2.52 (1.97–3.21) < 0.0001
20–44 884,372 (0.3) 313,505,459 (99.7) Referent – Referent –
Sex
Female 3,055,558 (0.5) 584,338,467 (99.5) 0.22 (0.20–0.25) < 0.0001 0.20 (0.18–0.24) < 0.0001
Male 8,714,139 (2.3) 368,523,233 (97.7) Referent – Referent –
Race
Other 574,306 (1.7) 32,942,130 (98.3) 1.43 (1.03–1.99) 0.0332 2.02 (1.47–2.77) < 0.0001
African-American 1,226,437 (1.2) 98,377,632 (98.8) 1.02 (0.82–1.27) 0.8513 1.33 (1.03–1.72) 0.0271
Caucasian 7,264,368 (1.2) 595,109,707 (98.8) Referent – Referent –
Ethnicity
Hispanic/Latino 511,614 (0.6) 78,750,878 (99.4) 0.49 (0.36–0.67) < 0.0001 0.64 (0.48–0.86) 0.0032
Non-Hispanic/Latino 8,252,946 (1.3) 622,092,211 (98.7) Referent – Referent –
Region
Northeast 2,019,734 (1.1) 187,761,102 (98.9) 0.90 (0.72–1.13) 0.3629 0.80 (0.62–1.03) 0.0823
Midwest 3,053,963 (1.5) 203,721,333 (98.5) 1.25 (1.04–1.52) 0.0169 1.16 (0.95–1.43) 0.1501
West 2,367,739 (1.2) 199,303,020 (98.8) 0.99 (0.80–1.24) 0.9580 0.86 (0.67–1.10) 0.2296
South 4,328,261 (1.2) 362,166,243 (98.8) Referent – Referent –
MSA
Non-MSA 1,709,090 (1.4) 119,137,057 (98.6) 1.18 (0.93–1.52) 0.1636 1.01 (0.77–1.32) 0.9462
MSA 10,060,607 (1.2) 833,724,642 (98.8) Referent – Referent –
Insurance Status
Other 407,967 (0.4) 98,328,703 (99.6) 0.43 (0.32–0.58) < 0.0001 0.51 (0.36–0.72) 0.0001
Medicaid 407,549 (0.5) 87,966,848 (99.5) 0.48 (0.35–0.66) < 0.0001 0.56 (0.39–0.80) 0.0014
Medicare 6,193,910 (2.2) 274,708,378 (97.8) 2.35 (2.07–2.68) < 0.0001 0.93 (0.74–1.15) 0.4846
Private Insurance 4,382,477 (0.9) 457,347,665 (99.1) Referent – Referent –
Setting Type
Hospital Emergency 353,199 (0.4) 94,359,329 (99.6) 0.28 (0.23–0.33) < 0.0001 0.42 (0.34–0.51) < 0.0001
Hospital Outpatient 892,347 (1.1) 77,244,784 (98.9) 0.86 (0.71–1.03) 0.0994 1.05 (0.88–1.26) 0.5718
Physician Office 10,524,151 (1.3) 781,257,587 (98.7) Referent – Referent –
Diuretic Use
Yes 3,575,442 (5.0) 67,667,807 (95.0) 5.71 (5.04–6.47) < 0.0001 4.00 (3.37–4.75) < 0.0001
No 8,194,254 (0.9) 885,193,893 (99.1) Referent – Referent –
MSA Metropolitan Statistical Area
* Survey weighting and clusters accounted for reflecting unbiased, national annual estimates of visit occurrences for the portion of the population meeting the
study inclusion/exclusion criteria
Note that per the model fitting criterion described in the methods section, no variables were excluded from the multivariable model
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Medicare vs. private insurance), hospital emergency de-
partments (vs. physician office visits) and diuretic use.
However, the associations between visits with a gout
diagnosis and region1 of the country and as well as gout
visits and Medicare (vs. private insurance) did not re-
main significant following adjustment for the effect of
the other covariates of interest in the model. A diagnosis
of gout remained more likely for patient visits in 2009–
2011 as compared to visits in 2007–2008 (OR 1.24, 95%
CI 1.02–1.52). Additionally, a diagnosis of gout remained
more likely for visits with patients 65 and older and pa-
tients 45–64 as compare to visits for those 20–44 (OR 4.
94, 95% CI 3.69–6.62 and OR 2.52, 95% CI 1.97–3.21,
respectively). Gout was less likely to be diagnosed at
visits for females as compared to males (OR 0.20, 95%
CI 0.18–0.24) and Hispanic/Latino patients as com-
pared to Non-Hispanic/Latino patients (OR 0.64, 95%
CI 0.48–0.86), while gout was more likely to be diag-
nosed at visits for those on a diuretic as compared to
those not on a diuretic (OR 4.00, 95% CI 3.37–4.75).
Gout was less likely to be diagnosed at patient visits
with an insurance status of “Other” and Medicaid as
compared to those with private insurance (OR 0.51,
95% CI 0.36–0.72 and OR 0.56, 95% CI 0.39–0.80, re-
spectively). Patients whose visit was recorded in an
emergency department were less likely (OR 0.42, 95%
CI 0.34–0.51) to be diagnosed with gout as compared
to those with a physician’s office visit (Table 2). Sec-
ond order interaction terms were investigated, found
to contribute nothing significant to the understanding
of the overall results and were excluded from the
final reported model.
Finally, plots of the percentage of patient visits with
gout by year for medication class and individual drug
showing the most common gout treatments can be seen
in Figs. 1 and 2. The percent of gout visits in each drug
class appears similar across the years studied. Antigout
(80–86%) and antihyperuricemic (67–75%) medications
were consistently the most common treatment while
NSAIDs (14–20%) and steroids (6–12%) were a distant
third and fourth, respectively.
Among individual medications, allopurinol (67–74%)
is clearly the most common, three to four times as likely
as the next closest (colchicine). Febuxostat, probenecid
and colchicine-probenecid were infrequently prescribed
(all less than 5%). Allopurinol and colchicine dominate
the market, their use appears consistent across the years
studied, while probenecid’s use has decreased over time.
Uptake does appear to be slow for febuxostat, the newest
gout medication, as two years after entering the market,
the percentage of patients with gout taking the drug re-
mains around 3%.
Discussion
The proportion of patient visits with a diagnosis of gout
increased between 2007 and 2011, and this increase was
significant. It is hypothesized that gout visits are on the
rise due to increases in obesity, hypertension, and
purine-rich diets [1, 2]. Obesity increases the production
of serum urate (sUA) levels and also decreases urate ex-
cretion while weight reduction has been associated with
uric acid level declination [16]. Along with risk factors,
there are many disease associations with gout including
metabolic syndrome, hypertension, and cardiovascular
disease [16]. Metabolic syndrome has been strongly as-
sociated with gout; 60% of US population with gout also
has metabolic syndrome, a prevalence three times higher
in those with gout [17]. Metabolic syndrome has likely
Fig. 1 Gout Prescription Trends by Drug Class, 2007–2011
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increased over the study years, helping explain the rise
in gout diagnoses [18].
The number of gout visits in this study was not as
high as noted in a similar prior study, [8] which could
be attributed to several different factors. Although not
specified in their methods, the Krishnan and Chen study
appears to have used aggregated estimates for the years
and databases studied, rather than the average annual
estimates used in this study. Additionally, Krishnan and
Chen only utilized NAMCS and NHAMCS-OPD,
whereas this study also utilized NHAMCS-ED. Despite
approximately 95 million visits attributed to the
NHAMCS-ED, visits for gout in the ED were less likely.
This likely increased the total number of overall visits
without adding a commensurate number of gout-specific
visits to the numerator. Further, while only 31% of the
study population was aged 65 or older, 61% was female
and the prevalence of gout is known to both increase
with age and be more prevalent in males [3].
Another prior study with higher gout estimates by
Zhu, et al. was based on participant reported data from
the National Health and Nutrition Examination Survey
(NHANES), which lends itself to estimating true preva-
lence [1]. This study is based on provider reported am-
bulatory, outpatient and emergency visits, therefore
limiting the ability to estimate the true prevalence of
gout. This database distinction helps explain this differ-
ence in gout estimates. It is worth noting that NHANES
as well as the data sources used for this study are all
population-based surveys.
The study results are consistent with several inter-
national epidemiology studies which examined the
prevalence of gout [19–23]. The prevalence of gout has
increased significantly in the United Kingdom (UK) over
the years of 1997 through 2012 according to a study
which utilized the Clinical Practice Datalink [19]. An-
other study which looked at gout prevalence in the UK
and Germany from 2000 to 2005 with the IMS Disease
Analyzer found a prevalence of 1.4% [20]. A study of the
Canadian province of British Columbia from 2000 to
2012 using PopulationDataBC found a prevalence of 3.
8% in 2012, and there was a noted increase over the
study period [21]. A Swedish study examined gout
trends from 2002 to 2012 and found a prevalence of 1.
8% in 2012 as well as an increase over the study period.
[22] A study in Taiwan utilizing the National Health In-
surance Research Database found a higher prevalence
rate of 6.24% over the study period of 2005 to 2010 [23].
With the exception of the Taiwan study [23], all studies
were consistent with this study’s findings with regards to
gout prevalence and increasing prevalence over the
years.
This study demonstrated an association between age,
sex, race group and gout visits, with an increased pro-
portion among older age groups (≥45 years of age),
males, African American and ‘Other’ race groups. These
finding are consistent with previous studies [1, 3, 8, 10]
showing that the risk of developing gout is age-related,
[1, 8] and that estrogen is protective in premenopausal
women due to its uricosuric effect [10]. ‘Other’ race
within the databases consists of Asian, Native Hawaiian
or other Pacific Islander, American Indian or Alaska Na-
tive, or more than one race reported. A higher preva-
lence of gout is well known in Asians and Pacific
Islanders, as well as African Americans with genetics
playing a role due to hyperuricemia-associated DNA se-
quence variations [24, 25]. However, diet and the pres-
ence of co-morbidities cannot be ruled out.
Fig. 2 Gout Prescription Trends by Individual Drug, 2007–2011
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Hispanic/Latino individuals were found to be less likely
to have a visit with gout than Non-Hispanic/Latinos. One
possible explanation is related to diet. A previous study
showed that Non-Hispanic/Latinos consume more red
meat and seafood when compared to Hispanic/Latinos.
[26] Diets rich in red meat and seafood are widely known
to be associated with the production of uric acid [2].
Given that Hispanic/Latino diets are typically more heav-
ily based on grains and beans along with fresh fruits and
vegetables, Hispanic/ Latinos may produce less uric acid
resulting in a lower incidence of gout [27].
Patient visits with Medicaid and ‘Other’ insurance
were less likely to have a diagnosis of gout. Despite the
lack of statistically significant interaction effects in the
multivariable model, this could be attributed to the role
of age with the risk of developing gout [1, 8]. ‘Other’ in-
surance consisted of worker’s compensation, self-pay, no
charge/charity, and other, while Medicaid also included
the Children’s Health Insurance Program. Patients with
‘Other’ insurance or Medicaid are less likely to be older,
the age group at the highest risk for gout.
Individuals were significantly less likely to have a visit
with a diagnosis of gout in a hospital emergency setting
than they were in a physician’s office. Patients are more
likely to visit a provider’s office for routine check-ups
and for chronic conditions like gout. While individuals
may visit a hospital for an initial or particularly severe
attack of gout, they are presumably more likely to visit
their provider when simply attempting to help keep their
gout under control. Furthermore, patients with gout are
much more likely to visit their provider if they are being
prescribed gout prophylaxis medication.
A study by Garg, et al. looked at gout-related health care
utilization in US emergency departments utilizing the Na-
tional Emergency Department Sample (NEDS) from 2006
to 2008 [28]. The Garg study found approximately 0.7% of
ED visits to be gout-related, slightly higher than 0.4%
found in this study [28]. A similar study by Jinno, et al.
also utilized NEDS and examined gout ED visits from
2006 to 2012 [29]. This study found 0.19% of visits with a
primary diagnosis of gout [29]. Although not exactly com-
parable to this study, which includes non-ED databases in
addition to the NHAMCS-ED, similar findings with both
of these studies include gout-related ED visits being more
likely with men, and increasing age; and less likely with
different insurance types [28, 29].
Diuretic use was four times more likely to be associated
with a gout visit. Previous research has shown that indi-
viduals who have high blood pressure and are also taking
a diuretic have an increased risk for acquiring gout [6].
The diuretics’ mechanism of action is thought to contrib-
ute to gout, increasing uric acid reabsorption [30].
The graph of gout medication class by year showed
consistency in use among the drug classes over the
years. Antigout and antihyperuricemic medication clas-
ses remained the two most commonly prescribed treat-
ments, while NSAIDs and steroids were used less. It is
worth noting that due to drug class coding within the
databases some medications could have been coded in
both the antigout and antihyperuricemic class (i.e., allo-
purinol and febuxostat) since drugs may be coded in as
many as four different medication classes. This might
explain why the antigout percentage is greater than the
antihyperuricemics. However, the findings in this study
are consistent with the prior NAMCS and NHAMCS-
OPD study which looked at gout treatment trends up
through 2009 [8]. These treatment trends can also be ex-
plained by typical prescribing patterns for a gouty attack
versus prophylaxis treatment to prevent gout flare.
NSAIDs and steroids are typically only used for gouty at-
tacks and patients are treated prophylactically after an
initial gout attack to prevent future attacks [2, 31]. In
addition, the risk of side effects with NSAIDs such as
gastrointestinal bleeds, renal failure, and hypertension
likely impacted their use in treatment, especially in the
case when chronic treatment is warranted [32, 33].
As evident from the figure showing the percentage of
visits by year for individual gout drugs, allopurinol con-
tinues to be the most prescribed treatment with colchicine
second, a finding also consistent with Krishnan and Chen
[8]. Allopurinol dominated the market as the only medica-
tion to reduce uric acid synthesis until the introduction of
febuxostat in 2009 [2, 4, 11]. As expected, the percentage
of visits with febuxostat increased following its approval.
Despite this, allopurinol and colchicine use changed little
from 2009 through 2011, evidence that febuxostat intro-
duction had minimal impact on the treatment trends for
the study years. Probenecid use has declined over the
years which can be explained by its potential for drug-
drug interactions as well as less favorable side effect pro-
file, including risk of urolithiasis [2, 11, 34].
The previously mentioned international studies showed
similar treatment trends. Allopurinol was prescribed for
most patients in UK and Germany at 89 and 93% respect-
ively; while colchicine use was only around 15–16% for
both [20]. Probenecid use was minimal (< 1%), but
NSAIDs were utilized 80–90% for prophylaxis. [20]. Allo-
purinol was also most commonly prescribed in British
Columbia, Canada, with less than 1% use of febuxostat and
probenecid [21]. Colchicine and steroid use increased in
British Columbia over the study period, while NSAID use
declined by 31% [21]. A study in Australia in 2005 found
allopurinol to comprise 98.4% of all urate lowering therapy
with probenecid at < 1% [35]. There was a common theme
from these studies of the overall underutilization of urate-
lowering treatment for gout [19–23, 35].
The study is not without limitations. The observational,
cross-sectional nature of the study design limited the
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authors to statements of association between visits with
gout diagnosis and the factors of interest. No claims of
causality can be made. Furthermore, the cross-sectional
nature of the data sources used did not allow for repeated
measurements on patients over time. Several variables of
interest, including alcoholism, Parkinson’s disease, depres-
sion, hypertension, weight status, tobacco use, and losar-
tan use had to be excluded from all analyses due to
missing data and/or reliability issues. This is particularly
unfortunate for variables such as hypertension and weight
status, both known to be significantly associated with
gout. All of the databases utilized are limited to three diag-
noses. The NAMCS and NHAMCS-OPD include a data
field to collect other specific disease states (includes hyper-
tension, diabetes, and depression), but NHAMCS-ED does
not and only collects the diabetes variable of interest in
their other specific disease field. This likely contributed to
the missing data for such highly prevalent conditions like
hypertension and diabetes. The NAMCS and NHAMCS
databases do not include federal offices or hospitals, includ-
ing Veterans Affairs facilities where gout can be prevalent.
In addition, the databases do not provide a true prevalence
of gout, but rather a surrogate via visits for gout based on
diagnostic codes from the three recorded diagnoses and
gout medications prescribed at the visits. It is not uncom-
mon for epidemiological studies to rely on diagnostic codes
for estimating prevalence. Those studies which have relied
on such codes have shown good accuracy. In addition, al-
though gout medications were also used to identify gout
visits, there is a chance that medications like colchicine and
probenecid were used for conditions other than gout. How-
ever, such alternative uses are rare. Study strengths include
the use of nationally representative, population-based sur-
veys which allow for generalizing findings to the portion of
the US population that is commensurate with the study
population. Further, the databases are provider reported
data which allows for more reliability of results as com-
pared to patient reported data. This is the first study known
to the authors to investigate febuxostat in the treatment of
gout since its approval in 2009 [4].
Conclusion
This study found that the proportion of visits with a
diagnosis of gout continues to increase, although the
overall percentage of gout remains low in the US popu-
lation. Individuals who are male, aged 45–64 or 65 and
older, non-Hispanic/Latino, African American or of
‘Other’ race, use private insurance, present to a physi-
cian’s office, or use a diuretic are more likely to have a
visit with a diagnosis of gout. Treatment trends over the
study years by medication class and individual gout
medications have remained consistent, with the intro-
duction of febuxostat having little impact for the study
years through 2011.
Poster presentations 2016 Wiggins Academic Sympo-
sium, Campbell University, Buies Creek, NC.
2017 Interprofessional Health Sciences Research Sym-
posium, Campbell University, Buies Creek, NC.
Endnotes
1The NAMCS and NHAMCS surveys define the four
regions that comprise this variable as follows:Northeast:
Connecticut, Maine, Massachusetts, New Hampshire,
New Jersey, New York, Pennsylvania, Rhode Island,
Vermont; Midwest: Illinois, Indiana, Iowa, Kansas,
Michigan, Minnesota, Missouri,Nebraska, North Dakota,
Ohio, South Dakota, Wisconsin; South: Alabama, Arkansas,
Delaware, District of Columbia, Florida, Georgia, Kentucky,
Louisiana, Maryland, Mississippi, North Carolina,Okla-
homa, South Carolina, Tennessee, Texas, Virginia, West
Virginia; West: Arizona, California, Colorado, Idaho,
Montana, Nevada, New Mexico, Oregon, Utah, Washington,
Wyoming, Alaska, Hawaii
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